Protocol design, emerging research, and the occasional letter from Basel. Written for researchers and practitioners who want context, not marketing copy.
A deep dive into the pharmacology, real-world data, and the gap between clinical trial outcomes and the popular narrative. With notes on what the research says — and what it doesn't.
Mechanistic rationale and published data for combining BPC analogs with thymosin beta-4. What the synergy actually looks like at the receptor level.
The difference between a clean peptide and a contaminated one often comes down to one test most vendors skip. An explainer on LAL assays and what <0.05 EU/mg actually means.
An inside look at the cGMP synthesis process, the culture of quality control, and what it means to hold pharmaceutical-grade standards in a research-use context.
A review of the circadian research behind Nocturne 02's evening cycle design. Why timing matters as much as dosing for sleep-targeted compounds.
Published guidance on receptor downregulation, wash-out periods, and the case for cycling peptide protocols. A practical framework for research cycle design.
One letter a month. The latest research, protocol notes, and behind-the-scenes from Basel. No product announcements, no promotions — just content worth reading.